FREE STOCK ALERTS
type here...
Monday, June 2, 2025
Claim Report Now: 758k Low Float Stock
FREE TRADING COURSE
spot_img
News Room
Less than 1 min.Read
romreal:-first-quarter-(q1)-2025-results-and-investor-presentation
RomReal: First Quarter (Q1) 2025 Results and Investor Presentation

RomReal: First Quarter (Q1) 2025 Results and Investor Presentation

Investing Today
By Investing Today

RomReal hereby announces the results of the first quarter of 2025 via the report and investor presentation attached to this message.

A webcast presentation will also be uploaded on our website www.romreal.com on 30 May 2025.

For further information please contact:

 

Investor Relations

RomReal

[email protected] 

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Attachments

  • RomReal Q1 2025 Report
  • RomReal Q1 2025 Presentation

Powered by SlickText.com

Hot this week

Topics

News Room

Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases

0
Tokyo, Japan and Cambridge, UK, 2 June 2025 –...
News Room

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant...

0
– New Drug Application based on positive results from...
News Room

Cenovus Energy provides operations update on impact of Alberta wildfires

0
CALGARY, Alberta, June 01, 2025 (GLOBE NEWSWIRE)...
News Room

Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050

0
All patients in the treatment arm remain disease-free after...
News Room

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

0
Median DOR of 21.7 months with 80% of responders...
News Room

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

0
Data Highlights Transformative Promise of CAR T in Solid...
News Room

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology...

0
- RP1 plus nivolumab generated robust responses in both...
News Room

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

0
33% reduction in relative risk of invasive disease observed...
spot_img

Related Articles

Popular Categories

News RoomFeatured CompaniesVideos
spot_img
Previous article
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
Next article
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies

Free News - Where voices unite, stories flourish, and community thrives through open dialogue and meaningful connections.

Company

Headlines

Newsletter

Get important news delivered directly to your inbox and stay connected!

© Investors Today 2024

SPDR S&P 500  SPY 
$589.39  0.11%  
Invesco QQQ Trust, Series 1  QQQ 
$519.11  0.16%  
Power Metallic Mines Inc.  PNPNF 
$0.755  0.40%  
NVIDIA Corporation  NVDA 
$135.13  2.92%  
Direxion Daily Junior Gold Mine  JNUG 
$75.13  2.04%  
POWER METALLIC MINES INC  PNPN.V 
$1.09  2.83%